Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection

AIDS

Volumn 12, Issue 13, 1998, Pages 1631-1637

  D'Arminio Monforte, Antonella ^b,c   Testa, Letizia ^b   Adorni, Fulvio ^a   Chiesa, Elisabetta ^b   Bini, Teresa ^b   Moscatelli, G Carla ^b   Abeli, Clara ^b   Rusconi, Stefano ^b   Sollima, Salvatore ^b   Balotta, Claudia ^b   Musicco, Massimo ^a   Galli, Massimo ^b   Moroni, Mauro ^b  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Compliance; Highly active antiretroviral therapy; Treatment failure

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DEATH; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; OBSERVATION; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TREATMENT FAILURE;

EID: 7344233149     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199813000-00010     Document Type: Article

References (17)

1. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1997, 351:543-549.
2. Hammer SM, Kathleen ES, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Enql J Med 1997, 337:725-733.
3. Clumeck N on behalf of the Saquinavir International Phase III Trial (SV 14604) Group: Clinical benefit of saquinavir (SQV) plus zalcitabine (ddC) plus zidovudine (ZDV) in untreated/minimally treated HIV-infected patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 28 Septemher to 1 October 1997 [abstract LB4].
4. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996, 276:146-154.
5. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 277:1962-1969.
6. Chiasson MA: Declining AIDS mortality in New York City. New York City Department of Health. Bull N Y Acad Med 1997, 74:151-152.
7. Mouton Y, Allandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997, 11:F101-F105.
8. USPHS/IDSA Prevention of Opportunistic Infections Working Group: 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997, 46 (RR-12):1-46.
9. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):19-23.
10. Noble S, Faulds D: Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112.
11. d'Arminio Monforte A, Vago L, Gori A, et al.: Clinical diagnosis of mycobacterial diseases versus autopsy findings in 350 patients with AIDS. Eur J Clin Microbiol Infect Dis 1996, 15:453-458.
12. Jacobson MA, Zegans M, Pavan PR, et al.: Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997, 349:1443-1445.
13. Mallolas J, Arrizabalaga J, Loncà M, et al.: Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors. AIDS 1997, 11:1785-1787.
14. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF: Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996, 276:1955-1956.
15. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
16. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
17. Fatkenheuer G, Theisen A, Roskstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.